Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non-Small Cell Lung Cancer

被引:23
|
作者
Obeng-Gyasi, Samilia [1 ]
Li, Yaming [2 ]
Carson, William E. [1 ]
Reisenger, Sarah [3 ]
Presley, Carolyn J. [3 ]
Shields, Peter G. [3 ]
Carbone, David P. [3 ]
Ceppa, DuyKhanh P. [4 ]
Carlos, Ruth C. [5 ]
Andersen, Barbara L. [6 ]
机构
[1] Ohio State Univ, Dept Surg, Div Surg Oncol, 410 W 10th Ave,Room N924 Doan Hall, Columbus, OH 43210 USA
[2] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA USA
[3] Ohio State Univ, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[4] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA
[5] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA
[6] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
NATIONAL SAMPLE; WOMENS HEALTH; SURVIVAL; SCORE; ADAPTATION; DISEASE; STRESS;
D O I
10.1001/jamanetworkopen.2022.21626
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Adverse social determinants of health (SDHs) (eg, poverty) are associated with poor oncologic outcomes among patients with lung cancer. However, no studies have evaluated biological correlates of adverse SDHs, operationalized as allostatic load (AL), with mortality due to lung cancer. OBJECTIVE To examine the association among AL, SDHs, and mortality among patients with metastatic non-small cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study of an observational cohort was performed at a National Cancer Institute-designated comprehensive cancer center with data accrued from June 1, 2017, to August 31, 2019. Patients with metastatic (stage IV) NSCLC enrolled at diagnosis into a prospective observational cohort study were included in the present analysis if they had all the biomarkers to calculate an AL score (N = 143). Follow-up was completed on August 31, 2021, and data were analyzed from July 1 to September 30, 2021. EXPOSURES Social determinants of health. MAIN OUTCOMES AND MEASURES Overall mortality and AL. RESULTS A total of 143 patients met the study criteria with a median age of 63 (IQR, 55-71) years (89 men [62.2%] and 54 women [37.8%]). In terms of race and ethnicity, 1 patient (0.7%) was Asian, 7 (4.9%) were Black, 117 (81.8%) were White, 17 (11.9%) were of multiple races, and 1 (0.7%) was of other race or ethnicity. The mean (SD) AL was 2.90 (1.37). Elevated AL covaried with lower educational level (r = -0.26; P = .002), male sex (r = 0.19; P = .02), limited mobility (r = 0.19; P = .04), worsening self-care (r = 0.30; P < .001), problems engaging in usual activities (r = 0.21; P = .01), depressive symptoms (r = 0.23; P = .005), and a high number of stressful life events (r = 0.30; P < .001). Multivariable analysis found only increasing difficulty with mobility (r = 0.37 [95% CI, 0.13-0.60]; P = .002) and male sex (r = 0.63 [95% CI, 0.19-1.08]; P = .005) associated with higher AL. On adjusted analysis, elevated AL (hazard ratio, 1.43 [95% CI, 1.16-1.79]; P = .001) and low educational level (hazard ratio, 2.11 [95% CI, 1.03-4.34]; P = .04) were associated with worse overall mortality. CONCLUSIONS AND RELEVANCE The findings of this cross-sectional study suggest that higher AL was associated with adverse SDHs and worse overall mortality among patients with advanced NSCLC. These results provide a framework for replication and further studies of AL as a biological correlate for SDH and future prognostic marker.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Management of Patients With Resectable and Metastatic Non-Small Cell Lung Cancer
    Yanagawa, Jane
    Riely, Gregory J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (5.5):
  • [22] Body Mass Index (BMI) Is Associated With Overall Survival in Patients With Metastatic Non-Small Cell Lung Cancer
    Medeiros, M. F.
    Spina Donadio, M. D.
    Simoes, M. F.
    Maciel Santana, D.
    De Andrade Souza, C. I.
    Mendes Gomes, L. B.
    Petrocchi Corassa, M.
    De Freitas, H.
    De Lima, V. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S308 - S309
  • [23] Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
    Cramer-van der Welle, Christine
    Peters, Bas J. M.
    Deenen, Maarten J.
    Schramel, Franz M. N. H.
    Van de Garde, Ewoudt M. W.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [24] Treatment patterns and overall survival in patients with BRAF-mutated metastatic non-small cell lung cancer
    Goyal, R. K.
    Kron, A.
    Wolf, J.
    Mazieres, J.
    Chouaid, C.
    Davis, K. L.
    Perrinjaquet, M.
    Knoll, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Overall Survival in Elderly Metastatic Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade
    Simoes, M. F.
    Medeiros, M. F.
    Maciel Santana, D.
    De Andrade Souza, C. I.
    Mendes Gomes, L. B.
    De Freitas, H.
    Petrocchi Corassa, M.
    Spina Donadio, M. D.
    De Lima, V. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S290 - S290
  • [26] Metastatic Non-Small Cell Lung Cancer to the Small Bowel
    Levy, Sara
    Shroff, Sagar
    Qayed, Emad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S421 - S421
  • [27] Spirometry at diagnosis and overall survival in non-small cell lung cancer patients
    Zhai, Ting
    Li, Yi
    Brown, Robert
    Lanuti, Michael
    Gainor, Justin F.
    Christiani, David C.
    CANCER MEDICINE, 2022, 11 (24): : 4796 - 4805
  • [28] Impact of smoking on mortality of patients with non-small cell lung cancer
    Lee, Seung Jun
    Lee, Jinwoo
    Park, Young Sik
    Lee, Chang-Hoon
    Lee, Sang-Min
    Yim, Jae-Joon
    Yoo, Chul-Gyu
    Han, Sung Koo
    Kim, Young Whan
    THORACIC CANCER, 2014, 5 (01) : 43 - 49
  • [29] Therapy of Metastatic Non-small Cell Lung Cancer
    Reinmuth, N.
    Groeschel, A.
    Schumann, C.
    Sebastian, M.
    Wiewrodt, R.
    Reck, M.
    PNEUMOLOGIE, 2016, 70 (09): : 567 - 578
  • [30] Immunotherapy of metastatic non-small cell lung cancer
    Sackmann, Sandra
    Ogundele, Samuel
    Ukena, Dieter
    PNEUMOLOGE, 2019, 16 (06): : 353 - 365